Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Tafluprost ethyl amide is a chemical compound and a prostaglandin F2alpha analog, derived from the medication tafluprost. It is designed to enhance the bioavailability and efficacy of tafluprost, which is commonly used in the treatment of glaucoma and ocular hypertension. Tafluprost ethyl amide works by reducing intraocular pressure through the increased outflow of aqueous humor from the eye, and is currently under investigation for its potential therapeutic applications in various ophthalmic conditions.

1185851-52-8

Post Buying Request

1185851-52-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1185851-52-8 Usage

Uses

Used in Ophthalmology:
Tafluprost ethyl amide is used as a therapeutic agent for the treatment of glaucoma and ocular hypertension. It functions by increasing the outflow of aqueous humor, thereby reducing intraocular pressure, which is crucial in managing these conditions and preventing further damage to the eye.
Used in Pharmaceutical Research and Development:
Tafluprost ethyl amide is utilized in the research and development of new ophthalmic medications. Its potential applications in treating various ophthalmic conditions make it a valuable compound for pharmaceutical companies and researchers seeking to innovate and improve treatment options for eye diseases.
Used in Drug Formulation:
As a derivative of tafluprost, Tafluprost ethyl amide is used in the formulation of new drug products aimed at enhancing the bioavailability and effectiveness of existing prostaglandin analogs. This can lead to improved patient outcomes and more efficient treatments for glaucoma and related eye conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 1185851-52-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,5,8,5 and 1 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1185851-52:
(9*1)+(8*1)+(7*8)+(6*5)+(5*8)+(4*5)+(3*1)+(2*5)+(1*2)=178
178 % 10 = 8
So 1185851-52-8 is a valid CAS Registry Number.

1185851-52-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]-N-ethylhept-5-enamide

1.2 Other means of identification

Product number -
Other names UNII-JJG9Y3YD25

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1185851-52-8 SDS

1185851-52-8Downstream Products

1185851-52-8Relevant articles and documents

A novel convergent synthesis of the potent antiglaucoma agent tafluprost

Krupa, Ma?gorzata,Chodyński, Micha?,Ostaszewska, Anna,Cmoch, Piotr,Dams, Iwona

, (2017)

Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde !-chain synthon 17. The use of the same prostaglandin phenylsulfone 16, as a starting material in parallel syntheses of all commercially available antiglaucoma PGF2α analogs 2-5, significantly reduces manufacturing costs resulting from its synthesis on an industrial scale and development of technological documentation. Another key aspect of the route developed is deoxydifluorination of a trans-13,14-en-15-one 30 with Deoxo-Fluor. Subsequent hydrolysis of protecting groups and final esterification of acid 6 yielded tafluprost (5). The main advantages are the preparation of high purity tafluprost (5) and the application of comparatively cheap reagents. The preparation and identification of two other tafluprost acid derivatives, tafluprost methyl ester (32) and tafluprost ethyl amide (33), are also described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1185851-52-8